Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Is There Any Difference in Clinical Outcomes Between Transient and Persistent Acute Kidney Injury in ACS Patients after Invasive Treatment?

Acute kidney injury (AKI) following acute coronary syndrome (ACS) is associated with prolonged hospital stay and worse prognosis at followup. However, serum creatinine level increase can either be transient or permanent. At present, retrospective studies show transient AKI patients present similar survival rate to patients with no AKI. The prognostic implications of transient and persistent AKI remain uncertain.   

Una nueva molécula para evitar la nefropatía por contraste

The aim of this sub-study was to assess transient vs. persistent AKI predictors and prognosis in ACS patients randomized to an invasive strategy for the multicenter MATRIX trial (Minimizing Adverse Hemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox).

Primary end point was major adverse cardiovascular events (MACE) at 30 days, defined as all cause death, AMI, stroke, and Net Adverse Cardiovascular Events (NACE) defined as the composite of MACE or BARCIII or V major bleeding. 

Secondary end point included primary end point components and cardiovascular mortality, transient ischemic attack, and target vessel revascularization. It also included ischemic events and bleeding at one year. 

Of a total 8201, AKI occurred in 16.3% of patients. 7.2% was transient and 9.1% persistent. Persistent AKI patients were older and mostly women. 

Read also: One Year Prognosis of Atherosclerotic vs. Non-Atherosclerotic Lesions in MINOCA Patients.

When comparing no AKI patients against persistent AKI patients, the latter showed higher MACE rate at 30 days (P<0.001) and one year (P<0.001). They were also associated to higher cardiovascular mortality rate and bleeding BARC III or V at 30 days (P<0.001) and one year (P<0.001). 

Transient AKI showed no differences in primary or secondary end points at 30 days but did show significant difference at one year as regards MACE (P=0.019) and all-cause and cardiovascular mortality (P=0.011). 

After multivariable analysis, while there was no difference against transient AKI patients, persistent AKI patients had higher MACE rate vs. no AKI patients (P<0.001) as well as higher all-cause mortality (P<0.001) at 30 days.  

Conclusion 

Persistent AKI was associated to higher MACE and NACE rates at 30 days in patients with acute coronary syndrome undergoing invasive treatment. However, this difference was not observed in transient AKI patients.   

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the editorial board of SOLACI.org.

Original Title: Transient vs In-Hospital Persistent Acute Kidney Injury in Patients With Acute Coronary Syndrome.

Reference: Antonio Landi, MD et al J Am Coll Cardiol Intv 2022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...